These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 33205837)

  • 1. Is there a difference in the effect between the ACEI and ARB on COVID-19?
    Chen J; Mei K; Deng C
    Clin Cardiol; 2021 Jan; 44(1):5-6. PubMed ID: 33205837
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term ACE Inhibitor/ARB Use Is Associated With Severe Renal Dysfunction and Acute Kidney Injury in Patients With Severe COVID-19: Results From a Referral Center Cohort in the Northeast of France.
    Oussalah A; Gleye S; Clerc Urmes I; Laugel E; Callet J; Barbé F; Orlowski S; Malaplate C; Aimone-Gastin I; Caillierez BM; Merten M; Jeannesson E; Kormann R; Olivier JL; Rodriguez-Guéant RM; Namour F; Bevilacqua S; Losser MR; Levy B; Kimmoun A; Gibot S; Thilly N; Frimat L; Schvoerer E; Guéant JL
    Clin Infect Dis; 2020 Dec; 71(9):2447-2456. PubMed ID: 32623470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antecedent Administration of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Antagonists and Survival After Hospitalization for COVID-19 Syndrome.
    Palazzuoli A; Mancone M; De Ferrari GM; Forleo G; Secco GG; Ruocco GM; D'Ascenzo F; Monticone S; Paggi A; Vicenzi M; Palazzo AG; Landolina M; Taravelli E; Tavazzi G; Blasi F; Infusino F; Fedele F; De Rosa FG; Emmett M; Schussler JM; Tecson KM; McCullough PA
    J Am Heart Assoc; 2020 Nov; 9(22):e017364. PubMed ID: 33023356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effects of angiotensin converting enzyme inhibitor/angiotensin receptor blocker on clinical characteristics of coronavirus disease 2019 patients with hypertension].
    Huang W; Li T; Ling Y; Qian ZP; Zhang YY; Huang D; Xu SB; Liu XH; Xia L; Yang Y; Lu SH; Lu HZ
    Zhonghua Nei Ke Za Zhi; 2020 Sep; 59(9):689-694. PubMed ID: 32838499
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to "COVID-19 and ACEI/ARB: Not Associated?".
    Schiffrin EL; Flack JM; Ito S; Muntner P; Webb RC
    Am J Hypertens; 2020 Aug; 33(8):789-790. PubMed ID: 32415836
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19 and ACEI/ARB: Not Associated?
    Hajra A; Bandyopadhyay D
    Am J Hypertens; 2020 Aug; 33(8):788. PubMed ID: 32415832
    [No Abstract]   [Full Text] [Related]  

  • 7. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection.
    Guo J; Huang Z; Lin L; Lv J
    J Am Heart Assoc; 2020 Apr; 9(7):e016219. PubMed ID: 32233755
    [No Abstract]   [Full Text] [Related]  

  • 8. Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19.
    Bae DJ; Tehrani DM; Rabadia SV; Frost M; Parikh RV; Calfon-Press M; Aksoy O; Umar S; Ardehali R; Rabbani A; Bokhoor P; Nsair A; Currier J; Tobis J; Fonarow GC; Dave R; Rafique AM
    Am J Cardiol; 2020 Oct; 132():150-157. PubMed ID: 32819683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In-hospital use of ACEI/ARB is associated with lower risk of mortality and critic illness in COVID-19 patients with hypertension.
    Yuan Y; Liu D; Zeng S; Wang S; Xu S; Wang Y; Yu R; Gao Y; Li H; Feng X; Zhou N; Zhao C; Gao Q
    J Infect; 2020 Nov; 81(5):816-846. PubMed ID: 32800800
    [No Abstract]   [Full Text] [Related]  

  • 10. Administration of ACEI or ARB in chronic kidney disease patients with concomitant SARS-CoV-2 respiratory infection.
    Mateo Gómez C; Martínez Del Río J; Piqueras Flores J
    Med Clin (Barc); 2021 Oct; 157(7):e295-e296. PubMed ID: 34059359
    [No Abstract]   [Full Text] [Related]  

  • 11. A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19.
    Volpe M; Patrono C
    Eur Heart J; 2021 Mar; 42(11):1061-1062. PubMed ID: 33659979
    [No Abstract]   [Full Text] [Related]  

  • 12. The other possible mechanism of the benefits of RAAS inhibition in the athogenesis of COVID-19.
    Gupta N; Patel K; Gupta R
    Clin Cardiol; 2020 Dec; 43(12):1349. PubMed ID: 33174213
    [No Abstract]   [Full Text] [Related]  

  • 13. COVID-19 and Angiotensin-Converting Enzyme Inhibitor/Angiotensin-Receptor Blocker Therapy.
    Kussmaul WG
    Ann Intern Med; 2020 Aug; 173(3):237-238. PubMed ID: 32422077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers.
    Gersh FL
    Mayo Clin Proc; 2020 Jul; 95(7):1552-1553. PubMed ID: 32622456
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative Impacts of ACE (Angiotensin-Converting Enzyme) Inhibitors Versus Angiotensin II Receptor Blockers on the Risk of COVID-19 Mortality.
    Zhou F; Liu YM; Xie J; Li H; Lei F; Yang H; Qin JJ; Cai J; Zhang XJ; Wu B; Xia M; Xiang D; Yang C; Ma X; Xu Q; Lu Z; Lu H; Xia X; Wang D; Liao X; Peng G; Yang J; Huang X; Zhang BH; Yuan Y; Wei X; Liu PP; Wang Y; Zhang P; She ZG; Xia J; Li H
    Hypertension; 2020 Aug; 76(2):e15-e17. PubMed ID: 32493070
    [No Abstract]   [Full Text] [Related]  

  • 16. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19.
    Diaz JH
    J Travel Med; 2020 May; 27(3):. PubMed ID: 32186711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of severe or lethal COVID-19, including Angiotensin Converting Enzyme inhibitors and Angiotensin II Receptor Blockers, in a sample of infected Italian citizens.
    Bravi F; Flacco ME; Carradori T; Volta CA; Cosenza G; De Togni A; Acuti Martellucci C; Parruti G; Mantovani L; Manzoli L
    PLoS One; 2020; 15(6):e0235248. PubMed ID: 32579597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Commentary on "angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may be harmful in patients with diabetes during COVID-19 pandemic".
    Ferrario CM
    Diabetes Metab Syndr; 2020; 14(5):1401-1402. PubMed ID: 32755842
    [No Abstract]   [Full Text] [Related]  

  • 19. Letter to the editor: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in developing a COVID-19 comorbidity-based host risk score.
    Vavougios GD
    Crit Care; 2020 May; 24(1):242. PubMed ID: 32430049
    [No Abstract]   [Full Text] [Related]  

  • 20. Update Alert: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults.
    Kansagara D; Mackey K; Vela K
    Ann Intern Med; 2020 Aug; 173(3):W66. PubMed ID: 32584593
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.